Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. more
Time Frame | BTAI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -12.07% | 0.67% | 0.49% |
1-Month Return | -36.77% | 0.26% | 5.96% |
3-Month Return | -34.22% | -6.21% | 9.35% |
6-Month Return | -75.87% | 1.69% | 14.4% |
1-Year Return | -89.32% | 11.41% | 32.23% |
3-Year Return | -98.1% | 12.87% | 33.15% |
5-Year Return | -93.89% | 48.89% | 95.23% |
10-Year Return | -96.3% | 109.26% | 191.11% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 24.30 | - | 375.00K | 1.38M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":27.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 156.00K | 188.00K | 297.00K | 20.00K | 1.26M | [{"date":"2019-12-31","value":12.38,"profit":true},{"date":"2020-12-31","value":14.92,"profit":true},{"date":"2021-12-31","value":23.57,"profit":true},{"date":"2022-12-31","value":1.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (156.00K) | 24.30 | (297.00K) | 355.00K | 120.00K | [{"date":"2019-12-31","value":-43.94,"profit":false},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":-83.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.8,"profit":true}] |
Gross Margin | - | 100.00% | - | 94.67% | 8.70% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":94.67,"profit":true},{"date":"2023-12-31","value":8.7,"profit":true}] |
Operating Expenses | 33.60M | 82.30M | 106.94M | 160.00M | 171.90M | [{"date":"2019-12-31","value":19.55,"profit":true},{"date":"2020-12-31","value":47.87,"profit":true},{"date":"2021-12-31","value":62.21,"profit":true},{"date":"2022-12-31","value":93.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (33.60M) | (82.30M) | (106.94M) | (159.65M) | (171.78M) | [{"date":"2019-12-31","value":-3360100000,"profit":false},{"date":"2020-12-31","value":-8229700000,"profit":false},{"date":"2021-12-31","value":-10693500000,"profit":false},{"date":"2022-12-31","value":-15964500000,"profit":false},{"date":"2023-12-31","value":-17178200000,"profit":false}] |
Total Non-Operating Income/Expense | - | 256.00K | 8.00K | (11.80M) | (13.88M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.13,"profit":true},{"date":"2022-12-31","value":-4608.2,"profit":false},{"date":"2023-12-31","value":-5422.27,"profit":false}] |
Pre-Tax Income | (32.97M) | (82.17M) | (106.93M) | (165.76M) | (179.05M) | [{"date":"2019-12-31","value":-3296800000,"profit":false},{"date":"2020-12-31","value":-8216900000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false}] |
Income Taxes | (633.00K) | (161.00K) | (301.00K) | 6.09M | 150.10K | [{"date":"2019-12-31","value":-10.39,"profit":false},{"date":"2020-12-31","value":-2.64,"profit":false},{"date":"2021-12-31","value":-4.94,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.46,"profit":true}] |
Income After Taxes | - | (82.01M) | (106.63M) | (171.85M) | (179.20M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17920310500,"profit":false}] |
Income From Continuous Operations | (32.97M) | (82.32M) | (106.93M) | (165.76M) | (211.60M) | [{"date":"2019-12-31","value":-3296800000,"profit":false},{"date":"2020-12-31","value":-8232400000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-21160500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (32.34M) | (82.01M) | (106.63M) | (171.85M) | (179.05M) | [{"date":"2019-12-31","value":-3233500000,"profit":false},{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false}] |
EPS (Diluted) | (2.02) | (3.79) | (4.08) | (5.91) | (6.15) | [{"date":"2019-12-31","value":-202,"profit":false},{"date":"2020-12-31","value":-379,"profit":false},{"date":"2021-12-31","value":-408,"profit":false},{"date":"2022-12-31","value":-591,"profit":false},{"date":"2023-12-31","value":-615,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BTAI | |
---|---|
Cash Ratio | 1.58 |
Current Ratio | 1.87 |
Quick Ratio | 1.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BTAI | |
---|---|
ROA (LTM) | -63.62% |
ROE (LTM) | -1766.94% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BTAI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.75 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.75 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BTAI | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.65 |
P/B | 3.97 |
Price/FCF | NM |
EV/R | 37.06 |
EV/Ebitda | NM |
BioXcel Therapeutics Inc (BTAI) share price today is $0.4078
Yes, Indians can buy shares of BioXcel Therapeutics Inc (BTAI) on Vested. To buy BioXcel Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BTAI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioXcel Therapeutics Inc (BTAI) via the Vested app. You can start investing in BioXcel Therapeutics Inc (BTAI) with a minimum investment of $1.
You can invest in shares of BioXcel Therapeutics Inc (BTAI) via Vested in three simple steps:
The 52-week high price of BioXcel Therapeutics Inc (BTAI) is $4.17. The 52-week low price of BioXcel Therapeutics Inc (BTAI) is $0.4.
The price-to-earnings (P/E) ratio of BioXcel Therapeutics Inc (BTAI) is
The price-to-book (P/B) ratio of BioXcel Therapeutics Inc (BTAI) is 3.97
The dividend yield of BioXcel Therapeutics Inc (BTAI) is 0.00%
The market capitalization of BioXcel Therapeutics Inc (BTAI) is $20.79M
The stock symbol (or ticker) of BioXcel Therapeutics Inc is BTAI